Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …

Various therapeutic advances have led to a paradigm shift in the clinical management of
patients with IBD. The introduction of immunosuppressive (such as azathioprine) and …

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Little is known about the optimal duration of therapy with an anti–tumor necrosis factor (TNF)
agent and/or an immunomodulator for patients with inflammatory bowel disease (IBD). We …

Background While mucosal healing has been proved to predict relevant clinical outcomes in
Crohn's disease (CD), little is known about the long‐term significance of transmural healing …

OBJECTIVES: Several decision algorithms based on the measurement of infliximab (IFX)
trough levels and antibodies to IFX have been proposed. Whether such algorithms can be …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Background and aims Treatment goals in inflammatory bowel diseases are evolving beyond
the control of symptoms towards the tight control of objectively-measured gastrointestinal …

There is a growing body of evidence reinforcing the unique connections between the host
microbiome, health, and diseases. Due to the extreme importance of the symbiotic …